Skip to main content
Premium Trial:

Request an Annual Quote

Biosearch Acquires Rights to TurboFish Technology

NEW YORK (GenomeWeb News) – Biosearch Technologies today announced it has acquired the exclusive worldwide rights to the turboFISH technology.

As a result, the Petaluma, Calif.-based firm maintains exclusive access to continuing Stellaris RNA FISH-based inventions from Rutgers University, it said.

TurboFish is a method for rapid single molecule RNA FISH. In a statement, Marc Beal, director of corporate development and licensing at Biosearch, said, "Point-of-care, point-of-contact, hospital bedside, and immediate care facilities are now target markets for real-time gene expression analysis using turboFISH. Extending turboFISH into the [operating room] for intraoperative analysis may allow for real-time cancer diagnostics, eliminating the need, ambiguities, and procedure of formalin fixation and paraffin embedding tissues for days-later analysis."

Financial and other terms of the deal were not disclosed.

Biosearch recently acquired a majority stake in LightSpeed Genomics. The two firms are co-developing a gene expression platform, optimized to work on Stellaris RNA FISH assays for detecting and quantifying single molecular RNA targets within individual cells.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.